Murex losses continue due to litigation costs:
This article was originally published in Clinica
Executive Summary
Canadian company International Murex Technologies reported sales of $50.4 million for the six months ended June 30th, 1996, up 6% on the same period in the previous year. The company's net loss was $1.3 million, compared with $3.2 million last year, which reflects the decreasing legal costs relating to HCV patent litigation against Chiron (see Clinica No 632, p 13). The company expects to return to profitability in 1996. Murex has now begun court proceedings against Abbott for patent infringement of its particle bound binding component immunoassay (see Clinica No 713, p 1).